Radiprodil not checked
GRIN Therapeutics, Inc. · RGH-896
FollowEvery change as it happens, and a Monday email
Trials
6 active
8 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.”In the company’s words, NCT06392009 on ClinicalTrials.gov
- Tested for
- GRIN-related Neurodevelopmental Disorder, Tuberous Sclerosis Complex, Focal Cortical Dysplasia, GRIN-related Disorders, Hepatic Impairment, GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function
- Main trialPhase 3
- “The Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-NDD) with a gain-of-function (GoF) genetic variant. This study will enroll two cohorts: one cohort of participants with a minimal number of countable motor seizures (with or without behavioral symptoms) (Phase 3 Cohort 1: Qualifying Seizures Cohort); and a second cohort with disease symptoms but no seizures or fewer…”In the company’s words, NCT07224581 on ClinicalTrials.gov
- Other names
- RGH-896
Other drugs for Tuberous Sclerosis Complex
- EverolimusNovartis · Phase 3
- YCJ-01 Full Spectrum cannbis ExtractOils4Cure · Phase 3
- SVG103Sovargen · Phase 1/2
- AV078Aeovian Pharmaceuticals, Inc. · Phase 2
- Sapu003SAPU NANO (US) LLC · Phase 1
- CannabidiolJazz Pharmaceuticals · Marketed (Phase 4 trial)
Coming up4
- NovPhase 1 trial completes · ClinicalTrials.gov
- May 2027Phase 3 trial completes · ClinicalTrials.gov
- May 2027Phase 1 trial completes · ClinicalTrials.gov
- Oct 2027Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07941206
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2027 | Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | |
| Phase 1/2Active, not recruiting | Jun 2026 | Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II | |
| Phase 1Active, not recruiting | 31 Oct 2026 | A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult Participants | |
| Phase 1Active, not recruiting | Nov 2026 | Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder | |
| Phase 1Recruiting | May 2027 | Radiprodil in Participants With Hepatic Impairment | |
| Phase 1Not yet recruiting | Oct 2027 | A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function Variants | |
| Phase 1Terminated | 8 Jul 2025 | Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults | |
| Phase 1Completed | 10 Jul 2025 | Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026